Metformin Hydrochloride Dawa

Metformin Hydrochloride, the active ingredient in Metformin Hydrochloride Dawa, is a biguanide presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving blood glucose control. The product complies with European Union pharmaceutical standards and is manufactured under GMP conditions. It is distributed in bulk and packaged forms suitable for institutional use. Metformin Hydrochloride Dawa is intended for prescription use only.

GNH USA supplies Metformin Hydrochloride Dawa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Hydrochloride is indicated for conditions related to impaired glucose metabolism and is used primarily in the management of type 2 diabetes. - Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels. - Prediabetes (impaired glucose tolerance): delays progression to overt diabetes when combined with lifestyle measures. - Polycystic ovary syndrome (off‑label): helps restore ovulatory cycles by lowering insulin resistance.

Metformin Hydrochloride may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite, typically mild and transient. - Diarrhea: frequent loose stools, especially during the first weeks of therapy, may improve with dose adjustment. - Metallic taste: a transient metallic sensation in the mouth that usually resolves.

Serious or Rare Side Effects: - Lactic acidosis: a rare but potentially fatal buildup of lactate, more likely in patients with renal impairment, heart failure, or severe infection. - Severe skin reactions: rare events such as Stevens‑Johnson syndrome or toxic epidermal necrolysis requiring immediate medical attention. - Hepatic dysfunction: significant elevation of liver enzymes or hepatitis, warranting discontinuation and monitoring.

When prescribing Metformin Hydrochloride, clinicians should consider several precautionary measures to minimize risks. - Renal function: assess eGFR before initiation and periodically thereafter. - Hepatic function: evaluate liver enzymes, as impairment may increase lactate risk. - Cardiovascular status: avoid in patients with acute or chronic hypoxia, heart failure, or recent myocardial infarction. - Concomitant medications: review for drugs that may affect renal clearance or increase lactic acidosis risk. - Pregnancy and lactation: weigh potential benefits against unknown fetal risks; use only if clearly needed. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Metformin Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure, increasing lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations, enhancing toxicity. - Alcohol abuse: potentiates risk of lactic acidosis and hypoglycemia.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycemia. - Diuretics (especially thiazides): can affect renal function and metformin clearance. - ACE inhibitors or ARBs: require monitoring of renal function and electrolytes.